Jazz Pharma Plc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Jazz Pharma Plc
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
/ 
Frequently asked questions
To buy Jazz Pharma Plc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Jazz Pharma Plc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Jazz Pharma Plc is JAZZ:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Jazz Pharma Plc has its primary listing on NASDAQ. You can trade Jazz Pharma Plc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Jazz Pharma Plc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Jazz Pharma Plc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Jazz Pharma Plc.